Table 3. Sensitivity analyses of efficacy of immunotherapy in patients with advanced NSCLC.

Type of immunotherapy*	Interventions	Number of trials	Pooled HR (95%CI)
Therapeutic vaccines	I vs. P	4	0.82 (0.70–0.94)
Immune checkpoint inhibitors	I vs. C	2	0.67 (0.53–0.80)
Other immunomodulators	I + C vs. C + (P)	2	1.01 (0.97–1.05)
	I vs. P	2	0.88 (0.52–1.24)

^*Studies that Jadad score less than 3 were excluded. I: immunotherapy; P: placebo; C: chemotherapy.